Infection risks of rituximab versus non‐rituximab treatment for rheumatoid arthritis: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Rheumatic Diseases"
DOI: 10.1111/1756-185x.13596
Abstract: The aim of this study was to assess the differences in infection rates between rituximab (RTX) and non‐RTX treatment in patients with rheumatoid arthritis (RA). read more here.
Keywords: risks rituximab; treatment; infection; rituximab versus ... See more keywords
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.00838
Abstract: PURPOSE The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE. METHODS Patients had confirmed symptomatic WM, either previously untreated… read more here.
Keywords: ibrutinib rituximab; placebo; innovate; plus rituximab ... See more keywords